{"id":"W4405045156","doi":"10.1182/blood-2024-204962","title":"Etavopivat Reduces Incidence of Vaso-Occlusive Crises in Patients with Sickle Cell Disease: HIBISCUS Trial Phase 2 Results through 52 Weeks","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Institutes of Health; Bausch Health; Novo Nordisk; CSL Behring; Bristol-Myers Squibb; Agios Pharmaceuticals; State of Connecticut Department of Public Health; Health Resources and Services Administration; bluebird bio","keywords":"Medicine; Vaso-occlusive crisis; Incidence (geometry); Internal medicine; Disease; Sickle cell anemia; Surgery; Gastroenterology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001606664,0.001065783,0.001470649,0.0002422952,0.0003161456,0.0008760193,0.0006081353,0.001114217,0.006315433],"category_scores_gemma":[0.0008755957,0.0004312312,0.001174296,0.0001976015,0.000434708,0.0007048374,0.0002915226,0.002055377,0.0008714283],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003583101,"about_ca_system_score_gemma":0.0006669057,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005206895,"about_ca_topic_score_gemma":0.001210975,"domain_scores_codex":[0.9997182,0.0001186443,0.0000224438,0.00005194746,0.00002924266,0.00005955901],"domain_scores_gemma":[0.9995333,0.00008311572,0.0001299137,0.000040758,0.00004867351,0.0001643844],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9092498,0.01707826,0.002822703,0.001061537,0.0008718917,0.0001183365,0.0001510566,0.0005637122,0.01402281,0.0001910173,0.003732945,0.050136],"study_design_scores_gemma":[0.8597369,0.1284862,0.007339984,0.00007534225,0.0003979035,0.0001358457,0.00003829669,0.0002968599,0.001348523,0.0001477357,0.001977514,0.00001898179],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9803512,0.007909938,0.0006723379,0.0008283667,0.0002048833,0.003406167,0.002741495,0.0001551195,0.003730657],"genre_scores_gemma":[0.9755095,0.004252003,0.001816778,0.001870436,0.000399198,0.00585185,0.00367055,0.00004062097,0.006588922],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006315433,"threshold_uncertainty_score":0.02112722,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009739962490781705,"score_gpt":0.2706558433956806,"score_spread":0.2609158809048989,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}